Aromatase inhibitors, bisphosphonates may lower mortality risk for postmenopausal women with early breast cancer - Research

A dose of aromatase inhibitors and bisphosphonates can potentially reduce the risk of mortality in postmenopausal women with early breast cancer, a recent study has found. According to a report published in The Lancet, a combination of the two drugs classes may also increase the benefits while cutting down some side effects.

As per a published report, Richard Gray, author of both studies, said the analyses "provide really good evidence that both of these inexpensive generic drugs can help to reduce breast cancer mortality in postmenopausal women."

The researchers have suggested these well-tolerated treatments should be considered for routine use in the treatment of early breast cancer in women with either a natural or medically induced menopause. This would not only extend lifespan but also cut down the adverse impact of cancer treatments.